Abstract 5680: MPSA-AB5000: a high-throughput membrane proteins screening array for therapeutic biologics specificity profiling

Le résumé fourni par la source

Abstract Antibody drug development is lengthy and complex, often hindered by various challenges in clinical advancement. Reports indicate that off-target binding of antibodies may be a significant issue, with approximately 25% of preclinical candidates potentially experiencing these off-target problems. With the rise of new modalities such as CD3 bispecific antibodies, ADCs, and CAR-T therapies, preliminary off-target screening of antibodies has become increasingly important. Despite the use of techniques like immunohistochemistry, ELISA, and flow cytometry (FACS) for off-target testing of antibodies, these methods still exhibit limitations in sensitivity, specificity, and throughput. To address the need for antibody target deconvolution and receptor identification, we developed a novel membrane protein screening array (MPSA) AB5000. MPSA-AB5000 is a high-throughput, cell-based platform for identifying antibody targets and off-targets, enhancing antibody specificity screening and reducing development risks. The MPSA-AB5000 covers diverse human membrane proteins, expressed in live cells to preserve native conformations. C-terminal epitope-tagged clones allow for expression confirmation and cellular localization. To provide the highest level of sensitivity, MPSA-AB5000 uses luciferase reporter cell line detection. The wash-free strategy reduces false negatives, and signal amplification makes remarkable discrimination. Compared to similar technologies, we possess significant advantages in the following aspects: a. High sensitivity and sigh throughput: our technology platform offers not only high sensitivity, capable of detecting subtle interactions but also supports high-throughput screening, allowing for the evaluation of a large number of samples in a short timeframe. b. Avoidance of false negative signals: by eliminating washing steps, our method reduces the risk of false negative signals, ensuring reliable detection of non-specific binding. c. Comprehensive validation approaches: we employ various validation methods such as FACS and ELISA to eliminate false positive signals, enhancing the accuracy and credibility of our results. All the advantages ensure that MPSA-AB5000 is more rapid, simple, and highly sensitive than traditional assays. Citation Format: Liping Wang, Yuanyuan Sun, Guoqian Wang, Jinying Ning, Feng Hao. MPSA-AB5000: a high-throughput membrane proteins screening array for therapeutic biologics specificity profiling [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5680.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.